High-dose therapy and autologous stem cell transplantation for children with HIV-associated non-Hodgkin lymphoma

Fluri, Simon; Ammann, Roland; Lüthy, Annette Ridolfi; Hirt, Andreas; Aebi, Christoph; Duppenthaler, Andrea; Leibundgut, Kurt (2006). High-dose therapy and autologous stem cell transplantation for children with HIV-associated non-Hodgkin lymphoma. Pediatric blood & cancer, 49(7), pp. 984-987. Hoboken, N.J.: Wiley-Liss 10.1002/pbc.20900

Full text not available from this repository. (Request a copy)

In contrast to adults, autologous stem cell transplantation (ASCT) as part of the salvage strategy after high-dose chemo/radiotherapy in human immunodeficiency virus (HIV) related Non-Hodgkin lymphoma (NHL) is not yet established for children. We report on a 13-year patient with congenital HIV infection and refractory Burkitt lymphoma, who was successfully treated by high-dose therapy (HDT) including rituximab followed by ASCT. After 26 months follow-up the patient remains in complete remission and his HIV parameters have normalized with continued highly active antiretroviral therapy (HAART). HIV infection may no longer exclude children from ASCT as part of salvage therapy. Pediatr Blood Cancer (c) 2006 Wiley-Liss, Inc.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
UniBE Contributor:	Fluri, Simon, Ammann, Roland, Hirt, Andreas, Aebi, Christoph, Duppenthaler, Andrea, Leibundgut, Kurt
ISSN:	1545-5009
ISBN:	16685736
Publisher:	Wiley-Liss
Language:	English
Submitter:	Anette van Dorland
Date Deposited:	04 Oct 2013 14:48
Last Modified:	05 Dec 2022 14:14
Publisher DOI:	10.1002/pbc.20900
PubMed ID:	16685736
Web of Science ID:	000250487800020
URI:	https://boris.unibe.ch/id/eprint/19998 (FactScience: 3077)